医药生物行业定期报告:创新药及CXO继续爆发,关注玫瑰痤疮(泰恩康/科笛)

华福证券
Jul 14, 2025

(以下内容从华福证券《医药生物行业定期报告:创新药及CXO继续爆发,关注玫瑰痤疮(泰恩康/科笛)》研报附件原文摘录)投资要点:行情回顾:本周(2025年7月7日-2025年7月11日)中信医药指数上涨1.8%,跑赢沪深300指数1.0pct,在中信一级行业分类中排名第16位;2025年初至今中信医药生物板块指数上涨12.8%,跑赢沪深300指数10.8pct,在中信行业分类中排名第6位。周涨幅前五...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10